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Metaplastic carcinomas of the breast (MCBs) are unusual neo-
plasms characterized by an admixture of glandular epithelial
components, which frequently exhibit features of squamous
differentiation, and mesenchymal malignant components. Re-
gardless of the presence of myoepithelial features in MCB, no
consensus concerning their putative histogenesis has yet been
achieved. Recently, novel putative myoepithelial markers have
been developed, including p63, maspin, and P-cadherin. We
assessed the expression of these myoepithelial markers in
MCBs and compared their expression with classic myoepithe-
lial markers. Immunohistochemistry using the streptavidin–
biotin–peroxidase complex technique with antibodies raised
against p63, maspin, P-cadherin, actin (clones CGA7, 1A4 and
HHF35), cytokeratin 14 (Ck14), and vimentin was performed
on 16 MCBs (7 matrix-producing MCBs, 6 adenosquamous
MCBs, and 3 MCBs with heterologous elements). In healthy
breast lobules and ducts adjacent to the tumors, myoepithelial
cells showed distinctive and consistent immunoreactivity for
p63, maspin, P-cadherin, actin, S-100 protein, and Ck14. Ma-
trix-producing MCBs were positive for maspin in all cases, for
p63 in 4 of 7 cases, and for P-cadherin in 4 of 7 cases. Ade-
nosquamous MCB showed immunoreactivity for p63, maspin,
and P-cadherin in 5 of 6 cases. All novel myoepithelial markers
and Ck14 decorated squamous cell islands. MCBs with heter-
ologous elements were positive for p63 in 1 case, for maspin in
all 3 cases, and for P-cadherin in 2 cases. All cases showed at
least one of the novel myoepithelial markers. Eleven of 16
cases were positive for actin. Eleven of 14 cases reacted with
Ck14, and all cases that stained for S-100 protein (9 of 9) and
vimentin (13 of 13) were also positive. Based on our findings,
the balance of probabilities favors that MCBs may have a basal
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Metaplastic carcinoma of the breast (MCB) is an um-
brella descriptive term that encompasses several types of
breast carcinomas that show the presence of peculiar
metaplastic elements (1–10). Since its first description,
several efforts have been driven to characterize its his-
togenesis, but most, if not all, of them fell short in
achieving this goal (1–10).
Recently, Perou et al. (11), using cDNA microarray
technology, described four distinctive patterns of gene
expression clustering in breast carcinomas, by which
they may be classified in four distinct gene expression
patterns: luminal epithelial and estrogen receptor–
positive pattern; normal breastlike pattern; c-erb-B2-
positive pattern; and basal cell and myoepithelial cell
pattern. Later, this research group (12) showed a corre-
lation between basal and c-erb-B2-positive groups with
an aggressive biologic behavior.
Because MCB shows mesenchymal-like spindle-
shaped cells or metaplastic elements, including bone,
cartilage, and squamous cells (1–10), and may geneti-
cally belong to the basal cell and myoepithelial cell pat-
tern, we attempted to evaluate the expression of maspin,
p63, and P-cadherin, which are molecules consistently
expressed by breast myoepithelial and basal (stem) cells.
Maspin, also known as mammary serpin, is a 42-
kilodalton protein that belongs to the serine protease in-
hibitor superfamily and presents an important role in
mammary development (13–16). It has been suggested
that maspin possesses tumor growth suppression, tumor
invasiveness suppression, and antiangiogenic properties
(13–16). In healthy breast tissue, its expression is almost
confined to the myoepithelial and stem cell compart-
ments of ducts and terminal ductulobular units (TDLUs)
(15–16). Recently, our group described the consistent
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expression of maspin in myoepithelial cell tumors of the
breast (16). Conversely, Lele et al. (15) and Maass et al.
(14) showed that a minor proportion of tubular and other
invasive carcinomas of the breast express maspin. To the
best of our knowledge, no systematic evaluation of
maspin expression in MCB has hitherto been performed.
p63 is a recently described p53 homolog nuclear tran-
scription factor that is necessary for mammary develop-
ment, as shown in knockout mouse models (17,18). The
TP63 gene encodes at least 6 distinct isoforms that har-
bor trans-activating (TAp63) or dominant-negative
(Np63) activities on the p53 reporter genes (17,18).
The Np63 is consistently expressed in the basal and
stem cell population of stratified epithelia and is thought
to be necessary for the maintenance of a somatic stem
cell population in these tissues (17,18). Recently, Bar-
bareschi et al. (18) evaluated Np63 and TAp63 expres-
sion in healthy breast tissue and human breast cancers.
Remarkably, they observed that Np63 was expressed in
the myoepithelial and the basal and stem cell compart-
ment of healthy breast and only rarely expressed by in-
vasive carcinomas and their metastases (18).
P-cadherin is a calcium-dependent glycoprotein that
plays a major role in homotypic–homophilic cell adhe-
sion (19–24). This molecule possesses an intriguing dis-
tribution in human epithelial cells, being restricted to
basal and stem cells of stratified epithelia, such as epi-
dermis and urothelium (19–24). In breast ducts and
TDLU, P-cadherin is confined to the membranes of myo-
epithelial and stem (basal) cells (19–24). Moreover, sev-
eral studies have pointed out a remarkable association of
P-cadherin expression in human breast carcinomas and
an embryonic myoepithelial and stem cell–like pheno-
type (20,21,23), which seems to be similar to the myo-
epithelial–basal–stem cell pattern described by Perou et
al. (11) and Sorlie et al. (12).
To analyze a putative myoepithelial and basal (stem)
cell histogenesis of MCB, we assessed the immunohis-
tochemical expression of these three myoepithelial and
stem cell markers in 16 bona fide cases of MCB and
compared them with classic myoepithelial markers,
-smooth muscle actin (ASMA), muscle-specific actin
(MSA), S-100 protein, cytokeratin 14 (Ck14), and vi-
mentin, which are variably, but consistently, expressed in
myoepithelial cell neoplasms.
MATERIAL AND METHODS
Sixteen cases of MCBs were retrieved from the con-
sultation files of two of the authors (E.M.P., F.C.S.). The
clinical pathologic information was obtained from the
surgical pathology reports and by contacting the refer-
ring pathologists.
Automated immunohistochemistry (Labvision Auto-
stainer LV-1) according to the streptavidin–biotin–
peroxidase techniques using antibodies raised against
maspin (clone EAW24, 1:50, Novocastra, Newcastle,
United Kingdom), p63 (clone 4A4, 1:150, Neomarkers,
Freemont, CA), P-cadherin (clone 56, 1:25, Transduc-
tion, Lexington, KY), MSA (clone HHF35, 1:50, DAKO
Corp., Carpinteria, CA), ASMA (clone CGA7, 1:5, Enzo
Diagnostics, New York, NY and clone 1A4, 1/1600,
DAKO Corp.), S-100 protein (polyclonal, 1:10,000,
DAKO Corp.), Ck14 (clone LL002, prediluted, Serotec
Ltd., Oxford, United Kingdom), and vimentin (clone V9,
1:400, DAKO Corp.) were performed on 4-m sections.
Previous heat-induced antigen retrieval with DAKO an-
tigen retrieval solution was performed. Positive and
negative controls were included in each slide run. All
controls gave satisfactory results. In addition, in all
samples, healthy breast lobules and ducts were available
as internal controls. Briefly, in nonneoplastic breast tis-
sue, maspin should stain the nuclei and cytoplasm of
myoepithelial cells of breast lobules and ducts (25). p63
should show nuclear positivity in myoepithelial cells of
nonneoplastic breast lobules and ducts. P-cadherin
should present a distinctive membranous and occasion-
ally cytoplasmic immunoreactivity in nonneoplastic
myoepithelial cells. MSA and ASMA should decorate
myoepithelial cells, vessel walls, and scattered stromal
cells. Cytokeratin 14 should stain myoepithelial cells of
the breast lobules and ducts.
Because nonneoplastic mammary secretory cells do
not express P-cadherin, either membranous or cytoplas-
mic, P-cadherin immunoreactivity was considered posi-
tive when more than 5% of the neoplastic cells expressed
this marker (18,22). Similarly, we adopted the same cut-
off value for nuclear and cytoplasmic maspin reactivity,
nuclear p63 reactivity, and cytoplasmic ASMA, MAS,
Ck14, and vimentin reactivity.
RESULTS
Clinical and Pathologic Findings
All patients were women, and their ages ranged from
43 to 78 years (mean, 61 years). Tumor size ranged from
0.9 to 6.5 cm (mean, 3.32 cm; median, 3.25 cm). All
cases were classified according to current criteria for
histologic classification of metaplastic breast carcinoma
(1,4–10). Seven cases showed the prototypical histologic
appearance of matrix-producing MCB (Fig. 1A). Three
cases were adenosquamous carcinoma of the breast (Fig.
1E). Three cases were spindle cell carcinomas of the
breast with rare to occasional squamous cell components
(two low and one high grade) (Fig. 2A), and three cases
were high grade breast carcinomas with heterologous
elements (Fig. 2E). Among the last three cases, Case 14
was composed of papillary projections lined by prolifer-
ated myoepithelial and secretory cells, sometimes ar-
ranged in tubulelike and papillary structures, admixed
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with atypical spindle cells arranged in a patternless fash-
ion, bone trabeculae, and chondroid foci. Case 15
showed an admixture of high grade invasive ductal car-
cinoma, squamous cell islands, chondroid areas, and
scattered highly pleomorphic cells. Case 16 was a het-
erogeneous neoplasm, composed of high grade solid ep-
ithelial areas, chondroid foci, and a large amount of pleo-
morphic multinucleated anaplastic cells. Table 1 summa-
rizes the clinical pathologic parameters of the patients.
Immunohistochemical Findings
All cases were positive for at least one myoepithelial
marker. Table 2 summarizes the immunohistochemical
findings.
Maspin
In the healthy myoepithelial cells of adjacent breast
lobules and ducts, maspin stained the nucleus and cyto-
plasm of myoepithelial cells. Nuclear or cytoplasmic
FIG. 1. Matrix-producing meta-
plastic carcinoma of the breast
(A–D). A: Medium-power mag-
nification of a matrix producing
metaplastic carcinoma of the
breast. B: Maspin immunoreac-
tivity in the epithelioid cells. C:
Focal p63 expression in the nu-
clei of neoplastic cells. D:
Strong cytoplasmic reactivity for
P-cadherin in neoplastic cells.
High grade adenosquamous
metaplastic carcinoma of the
breast (E–H). E: Medium-power
magnification of a high grade
adenosquamous carcinoma of
the breast. Note the presence of
a focus of squamous differentia-
tion on the right. F: Maspin posi-
tivity in the nuclei and cyto-
plasm of neoplastic cells. Note
that maspin decorated myoepi-
thelial cells in “normal” lobules
on the lower center. G: p63 ex-
pression in neoplastic cells of
the typical carcinomatous com-
ponent and in the squamous
cell component. Note that some
of the nuclei of the terminally
differentiated squamous cells
fail to highlight for p63. H: Neo-
plastic cells strongly stained
with P-cadherin in a membra-
nous and cytoplasmic distribu-
tion (A, E, hematoxylin and eo-
sin; B–D, F–H, streptavidin–
biotin–peroxidase and DAB).
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maspin expression was observed in 15 of 16 (93.75%)
MCBs; a concurrent nuclear and cytoplasmic staining
was found in 12 cases. In three additional cases, only a
cytoplasmic immunoreactivity pattern was highlighted.
Maspin immunoreactivity was detected in all seven ma-
trix-producing MCBs (Fig. 1B), in all three adenosqua-
mous MCBs (Fig. 1F), in two of three (66.67%) spindle
cell MCBs (Fig. 2B), and in all three MCBs with heter-
ologous elements (Fig. 2F). In one spindle cell MCB, one
matrix-producing MCB, and one MCB with heterolo-
gous elements, maspin was restricted to the cytoplasm of
the neoplastic cells. It is noteworthy that maspin was also
observed in most of the squamous cell differentiation
foci (Cases 1, 2, 4–6, and 15).
p63
In all control areas, p63 expression was observed in
the nucleus of myoepithelial cells of adjacent nonneo-
plastic breast lobules and ducts. p63 was observed in the
nuclei of neoplastic cells in 10 of 16 (62.5%) MCBs,
distributed as such: 4 of 7 (57.14%) matrix-producing
MCBs (Fig. 1C), 2 of 3 (66.67%) adenosquamous MCBs
(Fig. 1G), 3 of 3 (100%) spindle cell MCBs (Fig. 2C),
and 1 of 3 (33.33%) MCBs with heterologous elements
FIG. 2. Low grade spindle cell
metaplastic carcinoma of the
breast (A–D). A: Medium power
magnification of a low grade
spindle cell carcinoma of the
breast. B: Cytoplasmic maspin
expression in the cytoplasm of
the epithelioid cells arranged in
cords and strands. C: p63 ex-
pression in the nuclei of epitheli-
oid cells. D: Cytoplasmic and
membranous P-cadherin expres-
sion in cells with similar morphol-
ogy and distribution. Carcinosar-
coma (metaplastic carcinoma
with heterologous elements) of
the breast (E–H). E: Low-power
view illustrating the complex ad-
mixture of tubulopapillary struc-
tures and metaplastic elements.
F: Maspin expression in the cells
arranged in papillary structures.
G: These same cells were also
decorated with p63 antibody.
Note on the left side the presence
of “normal” ducts with p63-
positive myoepithelial cells. H: P-
cadherin expression in tubulo-
papillary structures (A, E, hema-
toxylin and eosin; B–D, F–H,
streptavidin–biotin–peroxidase
and DAB).
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(33.33%) (Fig. 2G). Nuclear expression of p63 was de-
tected in the foci of squamous cell differentiation (Cases
1, 2, and 4—6).
P-cadherin
In adjacent control breast lobules and ducts, P-
cadherin highlighted the membrane of myoepithelial
cells. P-cadherin cytoplasmic or membranous immuno-
reactivity was observed in 11 of 16 cases, including 4 of
7 (57.14%) matrix-producing MCBs (Fig. 1D), 3 of 3
(100%) adenosquamous MCBs (Fig. 1H), 2 of 3
(66.67%) spindle cell MCBs (Fig. 2D), and 2 of 3
(66.67%) MCBs with heterologous elements (Fig. 2H).
In five cases (Cases 1–4 and 6), cytoplasmic expression
of P-cadherin was highlighted in squamous cell nests.
Classic Myoepithelial Markers
For classic myoepithelial markers, ASMA and MSA
decorated myoepithelial cells of breast lobules, ducts,
and vessel walls and showed immunoreactivity in scat-
tered stromal cells. S-100 protein showed strong nuclear
and cytoplasmic positivity in myoepithelial cells, nerve
bundles, scattered stromal cells, and some epithelial se-
cretory cells. Ck14 consistently decorated the cytoplasm
of myoepithelial cells of ducts but also showed a variable
reactivity in lobules. ASMA showed divergent results
according to the different clones we used in the current
study. Whereas 6 of 8 cases showed rather remarkable
immunoreactivity for 1A4 clone (3 matrix-producing
MCBs, 2 spindle cell MCBs, and 1 MCB with heterolo-
gous elements), 8 of 16 cases were immunoreactive for
clone CGA7 (3 matrix-producing MCBs, 1 high grade
adenosquamous carcinoma, 2 low grade spindle cell car-
cinomas with squamous cells, and 2 MCBs with heter-
ologous elements). MSA was positive in all cases evalu-
ated (one high grade spindle cell MCB with rare squa-
mous cells, one low grade spindle cell MCB with rare
squamous cells, and four matrix-producing MCBs). Nine
cases were evaluated for S-100 protein immunoreactiv-
ity; in all cases, S-100 positivity was observed (two low
grade adenocarcinomas with squamous cells, five ma-
trix-producing MCBs, and two MCBs with heterologous
elements). Ck14 immunoreactivity was assessed in 14
cases; in 11 cases, a rather strong and multifocal Ck14
expression was found. Four of five matrix-producing
MCBs, three of four high grade spindle cell carcinomas,
TABLE 2. Expression of myoepithelial cell markers in metaplastic carcinomas of the breast
Case Histological type P63 Maspin P-Cad ASMA* ASMA** SMA S-100 CK14 Vim
N C
1 High grade Adenosquamous MCB + + + + − N.A. N.A. N.A. − N.A.
2 High grade adenosquamous MCB + + + + + N.A. N.A. N.A. + N.A.
3 High grade adenosquamous MCB − + + + − N.A. N.A. N.A. + ++
4 High grade spindle cell MCB (rare squamous cells) + + + + − N.A. + N.A. + ++
5 Low-grade spindle cell MCB (rare squamous cells) + − − − + + + + + +
6 Low-grade spindle cell MCB (rare squamous cells) + − + + + + N.A. + + +
7 Matrix producing MCB + + + − + N.A. N.A. N.A. + +
8 Matrix producing MCB + + + + − − N.A. + N.A. +
9 Matrix producing MCB − + + + − − + + − +
10 Matrix producing MCB − − + − − + N.A. + + +
11 Matrix producing MCB + + + − − N.A. + N.A. N.A. N.A.
12 Matrix producing MCB − + + + + + + + + +
13 Matrix producing MCB + + + + + + + + + +
14 MCB with heterologous elements + + + + + + N.A. + + +
15 MCB with heterologous elements − − + − + N.A. N.A. N.A. − +++
16 MCB with heterologous elements − + + + − N.A. N.A. + + +
ASMA, -smooth muscle actin; C, cytoplasmic; CK14, Cytokeratin 14; MCB, metaplastic carcinoma of the breast; MSA, muscle specific
actin; N, nuclear; N.A., not available; P-Cad, P-cadherin; SMA, smooth muscle actin; Vim, vimentin.
*: Enzo Diagnostics, clone CGA7, 1:5
**: DAKO, clone 1A4, 1/1600
Note: ASMA**, SMA, S-100 protein, cytokeratin 14, and vimentin were done in 8, 6, 8, 14, and 13 cases, respectively, due to restrains
in paraffin-embedded tissue availability.
TABLE 1. Clinicopathological findings of metaplastic






1 71 3.5 2
2 78 4.2 3
3 64 3.3 3
4 43 4.5 2
5 74 6.5 2
6 66 3.1 2
7 43 3.2 3
8 68 2.1 3
9 75 2 3
10 N.A. 0.9 3
11 44 3 2
12 43 1.5 3
13 74 3.6 3
14 75 3.8 2
15 52 5 3
16 45 2.9 3
N.A., not available.
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two of two low grade spindle cell carcinomas with scat-
tered squamous cells, and two of three MCBs with het-
erologous elements were positive for this marker.
Vimentin
Vimentin was evaluated in 13 cases. In the adjacencies
of the neoplasms, vimentin decorated intralobular and
perilobular stromal cells and vessel walls. Remarkably,
vimentin was positive in all 13 cases evaluated in the
current study.
DISCUSSION
The histogenesis of metaplastic breast carcinoma has
challenged pathologists since the early days of diagnostic
surgical pathology (1–10). In 1987 Oberman et al. (5)
coined the designation “metaplastic carcinoma of the
breast” as a term to describe a group of biphasic carci-
nomas of the mammary gland that are characterized by a
mixture of glandular epithelial components, which fre-
quently exhibit features of squamous differentiation, and
mesenchymal malignant components with highly vari-
able histologic features, including spindle cells, bone,
cartilage, myxoid stroma, and anaplastic stroma with gi-
ant cells (1,5–10).
Initially, MCBs were regarded as “collision tumors,”
but molecular genetic studies, by means of HUMARA
clonality assays or by the finding of concurrent genetic
alterations in glandular and mesenchymal cells, support
a clonal ontogeny of the different components of
MCBs (26–28).
Because MCBs are clonal tumors, the question that
still remains unanswered is the origin of these neo-
plasms. Conflicting data have been published regarding
the histogenesis and differentiation of MCB (1,3,5,7,29–
32). Whereas some authors have favored a myoepithelial
cell histogenesis (1,5,7,29,30,31), others have refuted
this hypothesis and have supported a secretory cell on-
togeny for these neoplasms (3). Several lines of indirect
evidence favors a putative myoepithelial histogenesis for
MCBs, including the presence of cufflike proliferation of
malignant cells around the residual breast ducts and
metaplastic changes, such as squamous, chondroid, os-
teous, and mesenchymal-like metaplasia, which are usu-
ally observed in reactive myoepithelial cells and in myo-
epithelial cell tumors of the breast, salivary, and sweat
glands (1,29–31). Conversely, these phenomena are ex-
ceedingly rare in epithelial secretory cells of the breast.
In addition, ultrastructural studies have also disclosed the
presence of myoepithelial features in bona fide cases of
MCB (32).
The current study brings new evidence for a myoepi-
thelial cell origin in this heterogeneous group of neo-
plasms. We observed maspin expression in 93.7%, p63
in 62.5%, and P-cadherin in 57.1% of MCB cases, re-
gardless of their histologic appearance. All cases were
positive for at least one of these markers.
There are compelling data that militates that maspin
may be used as a reliable myoepithelial marker (15,
16,25), because it consistently decorates nonneoplastic
and neoplastic myoepithelial cells and, at variance,
only rarely stains nonneoplastic or neoplastic secretory
cells (14–16,25).
Similar results regarding p63 expression were ob-
served by Barbareschi et al. (18) in a series of 300 in-
vasive carcinomas of different histotypes (18). These au-
thors found that p63 expression was restricted to the
adenoid-cystic carcinomas, metaplastic carcinomas with
squamous metaplasia, and 4.6% of ductal carcinomas not
otherwise specified (18). Wang et al. (28) also evaluated
p63 expression in a unique case of metaplastic breast
carcinoma that coexhibited squamous and cartilaginous
metaplastic components; in this case, p63 expression was
restricted to the squamous component. Our results cor-
roborate those observed by Barbareschi et al. (18) and
Wang et al. (28); we observed p63 expression in two of
three cases of MCB with squamous metaplasia. A pre-
viously unreported finding of the current study is that
p63 was strongly expressed in the nuclei of neoplastic
spindle cells in low grade spindle MCB with or without
squamous metaplasia (Fig. 2C). In our view, further stud-
ies are needed to evaluate the putative role of this marker
in immunohistochemical panels designed for the differ-
entiation between spindle cell MCB and other spindle
cell lesions of the breast.
A large amount of data has been published in the last
few years addressing P-cadherin expression in invasive
and in situ breast carcinomas. In the different studies,
P-cadherin expression ranged from 20% to 52% (19–
22,24) of invasive breast carcinomas, independent of the
histologic type. P-cadherin-positive cases were associ-
ated with high proliferation rates, lack of estrogen and
progesterone receptors, c-erb-B2 overexpression, p53
immunoreactivity, lymph node metastasis, and poor sur-
vival (19–22,24). Moreover, it has been shown that some
special types of breast carcinomas are consistently im-
munoreactive for this marker, namely the metaplastic
and medullary variants (20,23). The biologic meaning of
P-cadherin in breast neoplasms is not well understood
(19–21,23). Peralta Soler et al. (24) and Gamallo et al.
(20) raised the hypothesis that aberrant expression of
P-cadherin in breast cancer cells is associated with an
embryonic phenotype similar to that of somatic stem
cells (20,22,24). Accordingly, P-cadherin expression was
consistently observed in those samples included in the
subgroup of breast carcinomas with basal and myoepi-
thelial cell–like mRNA profile described by Perou et al.
(11). Han et al. (23) reported P-cadherin expression in all
cases of sarcomatoid MCB (spindle cell MCB) and
carcinosarcoma (MCB with heterologous elements). Our
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study supports the finding of Han et al.(23) because two
of three spindle cell MCBs and two of three MCBs with
heterologous elements (carcinosarcomas) were positive
for P-cadherin.
To further characterize whether tumors positive for
one of the novel myoepithelial markers also showed a
myoepithelial or stem (basal) cell phenotype, we also
evaluated the expression of classic myoepithelial mark-
ers (ASMA in all cases and MSA and S-100 protein
immunohistochemistry for selected cases because of re-
strictions in tissue availability). Because these classic
markers are related to the smooth muscle apparatus and
properties of myoepithelial cells, one would expect that
myoepithelial cells, myoepithelial-derived tumors, and
tumors with partial myoepithelial differentiation would
express them, whereas undifferentiated stem (basal) cells
and their tumors would not (18). We found a high fre-
quency of classic myoepithelial markers expression in all
histologic types of MCB. Our results are in accordance
with the largest studies on MCB published to date, in
which immunoreactivity for actin or S-100 protein was
frequently observed in low and high grade spindle cell
carcinomas (2,7,32,33), matrix-producing MCB (6), and
so-called carcinosarcomas (8,34).
Cytokeratin 14 is an acidic cytokeratin that is positive
in basal cells of stratified epithelia and myoepithelial
cells of the breast and salivary glands (35). It is consis-
tently expressed in squamous cell carcinomas (35), ad-
enomyoepitheliomas of the breast (36), and myoepithe-
lial tumors of the salivary glands (35,36). Conversely, it
is usually negative in most adenocarcinomas and espe-
cially in ductal and lobular carcinomas of the breast (35).
Noteworthy, it has been advocated that Ck14 can be used
to consistently support a diagnosis of myoepithelial cell
tumors (35). We observed Ck14 expression in 11 of 14
cases of MCBs; thus, the balance of probabilities favors
a myoepithelial or stem cell (basal cell) histogenesis or
differentiation in MCBs.
Experimental data also support a myoepithelial cell
histogenesis for MCB. Sapino et al.(37), using rat
R3230AC mammary tumor-derived cell lines that dis-
play clones with epithelial and myoepithelial pheno-
types, demonstrated that myoepithelial clone-derived tu-
mors usually grew in a sarcomatous or carcinosarcoma-
tous pattern, whereas epithelial-derived tumors presented
a carcinomatous pattern (37). Altogether, these findings
may rather support a myoepithelial phenotype instead of
a basal or stem cell phenotype.
In conclusion, we reported a consistent expression of
novel and classic myoepithelial markers in MCB. Al-
though the entity of MCB encompasses a highly hetero-
geneous group of neoplasms, our findings and previously
reported data support that most MCBs may have a
myoepithelial histogenesis or harbor a myoepitheli-
al differentiation. 
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